Compare Gilead Sciences, Inc. (GILD) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs McCormick & Company, Incorporated — how do they compare? Gilead Sciences, Inc. trades at $133.55 (market cap $163.51B), while McCormick & Company, Incorporated trades at $52.3 (market cap $13.70B). The key difference: Gilead Sciences, Inc. is far larger — about 11.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| GILD | MKC | |
|---|---|---|
Market Cap | $163.51B | $13.70B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $72.81 |
52-Week Low | $108.22 | $45.60 |
Enterprise Value | $178.05B | $18.30B |
Dividend Yield | 2.49% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
McCormick (MKC) trades at $52.85, down 1.67% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67. The company reported strong Q2 2026 earnings of $0.80 per share, beating estimates, driven by acquisitions and margin expansion. Recent news highlights the transformative potential of the Unilever Foods deal, while financials show steady revenue growth and a net income margin of 21.91% for 2025.
The outlook is positive with 36.67% of analysts rating it a buy, citing undervaluation and strategic deals, but risks include soft consumer volumes and integration challenges. Upside hinges on execution of cost savings and volume recovery, with the current P/E of 8.47 suggesting value if growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
